Cel Sci Corp financial data

Symbol
CVM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
8229 Boone Blvd ., Suite 802, Vienna, Virginia
State of incorporation
Colorado
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 119 % -63.9%
Debt-to-equity 133 % +73.3%
Return On Equity -234 % -65.9%
Return On Assets -100 % -25.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.5M shares +30.1%
Common Stock, Shares, Outstanding 54.3M shares +21.3%
Entity Public Float 97.6M USD -83.6%
Common Stock, Value, Issued 543K USD +21.3%
Weighted Average Number of Shares Outstanding, Basic 43.4M shares +0.84%
Weighted Average Number of Shares Outstanding, Diluted 44.4M shares +3.15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19M USD -19.9%
General and Administrative Expense 8.75M USD -5.85%
Operating Income (Loss) -27.7M USD +16%
Net Income (Loss) Attributable to Parent -28.4M USD +13.9%
Earnings Per Share, Basic -0.18 USD/shares +10%
Earnings Per Share, Diluted -0.85 USD/shares +4.49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.14M USD -81.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 2.35M USD
Assets, Current 3.54M USD -54.2%
Property, Plant and Equipment, Net 8.61M USD -19.3%
Operating Lease, Right-of-Use Asset 1.55M USD -11.4%
Assets 24.1M USD -25.5%
Accounts Payable, Current 1.37M USD -21.4%
Accrued Liabilities, Current 1.27M USD +11.5%
Liabilities, Current 5.51M USD +4.04%
Operating Lease, Liability, Noncurrent 1.49M USD -12.8%
Other Liabilities, Noncurrent 125K USD 0%
Liabilities 15.6M USD -11%
Retained Earnings (Accumulated Deficit) -508M USD -5.93%
Stockholders' Equity Attributable to Parent 8.47M USD -42.7%
Liabilities and Equity 24.1M USD -25.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.89M USD -4.74%
Net Cash Provided by (Used in) Financing Activities 4.05M USD +6089%
Net Cash Provided by (Used in) Investing Activities -64.9K USD -21.1%
Common Stock, Shares Authorized 600M shares 0%
Common Stock, Shares, Issued 54.3M shares +21.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 385K USD -92.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 245K USD -11.9%
Deferred Tax Assets, Valuation Allowance 60M USD +13.3%
Deferred Tax Assets, Gross 62.7M USD +11.5%
Operating Lease, Liability 1.71M USD -10.3%
Payments to Acquire Property, Plant, and Equipment 51.7K USD -3.6%
Lessee, Operating Lease, Liability, to be Paid 2.35M USD
Property, Plant and Equipment, Gross 18.1M USD +2.22%
Operating Lease, Liability, Current 219K USD +14.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 287K USD -21.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 366K USD +2.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 640K USD -20.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 277K USD -3.48%
Deferred Tax Assets, Operating Loss Carryforwards 30.8M USD +21.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 285K USD +2.89%
Operating Lease, Payments 85K USD +28.8%
Additional Paid in Capital 516M USD +4.46%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 7K USD -22.2%
Deferred Tax Assets, Net of Valuation Allowance 60M USD +13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%